Base editing reached human trials, but the FDA's April 2026 NGS safety draft guidance reveals how far the regulatory ...
ICU staffing emerges as critical factor in ARDS trial enrollment, with site selection now prioritizing round-the-clock ...
AHN Cancer Center launches RANDY'S Trial to test FDA-approved drugs for treating peritoneal fibrosis in abdominal cancer ...
Evident launches Pramana POD scanner for small pathology labs, processing 25 slides per hour with built-in quality assessment ...
FDA Approves RYZUMVI for presbyopia treatment in adults. Viatris seeks commercial partner to bring the phentolamine eye drop to market.
Payers report inconsistent ESR1 testing practices for advanced breast cancer, creating delays in targeted SERD treatment despite clinical evidence supporting ea ...
CluePoints earns third Scrip Awards shortlisting in eight years for its risk-based quality management software serving ...
RBQM's $13.8M value driven 84% by Phase III timeline gains, with clinical phase durations shrinking up to 19% in oncology ...
Entrada Therapeutics reports Phase 1/2 data for ENTR-601-45 in exon 45 skipping, the most common single-exon target affecting ...
Vanda Pharmaceuticals' VQW-765 fails primary endpoint in Phase III social anxiety trial, showing no statistically significant ...
RBQM's full value exceeds current financial models, with omitted factors like rework reduction and inspection readiness ...
“Study builds [in TrialKit] went from anywhere from two to six weeks to one to three to four days. The work Floyd is doing on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results